Unlocking the future of RNA therapeutics

Breakthrough tech for a new era of biotherapy

Cutting-edge Proprietary Technology
Proven Track-Record
Unparalleled Expertise
Versatile Applications
Regulatory Compliance
End-to-End Support
GMP Readiness

RNAlead, Disruptive RNA Delivery with a Proven Alternative to Current Technologies

RNAlead was created to provide our cutting-edge proprietary RNA delivery technology platform in a customized end-to-end solution, including manufacturing tech-transfer and licensing solutions.

Designed to be more efficient, more accessible, and clinic-ready, our platform sets a new standard for safer, targeted RNA-based therapeutics.

RNA for FlashRNA^® technology

Lead for cell targeting

Leading the Next Frontier of Therapeutic Innovation

At the heart of our innovation lies the versatility of our RNA delivery system, enabling a wide range of therapeutic applications. This adaptability positions RNAlead as a key player in the biotherapy market, offering a strong competitive edge and opening new frontiers for next-generation treatments.

Our technology

FlashRNA^® is an innovative RNA transfer tool, combining the external structure of a lentivirus associated with a specific RNA packaging system derived from bacteriophages.
This unique combination associates the efficient cell transfer capability of lentiviral vectors with the recruitment of multiple RNA molecules manufactured through a biological process. FlashRNA^® thus offers unrivalled performance and safety for multiple RNA delivery, in vitro as well as in vivo.
A particle carrying a biological RNA manufactured with a 100% biological process, which is ready for therapy as a drug product, thanks to a validated scale-up.

The next mRNA gold standard

FlashRNA® technology is a patented, proprietary RNA-competent vector with over 10+ years of proven expertise. It is a disruptive, fully owned alternative to LNPs that is compatible with different and large RNA payloads and can be administered via various routes for a wide range of indications.

FlashRNA^® positions itself as the RNA delivery solution for next-generation advanced therapies.

Multiple & different RNA delivery

Thanks to its unique features, FlashRNA^® can carry various RNA species at once.

Low immunogenicity

Because RNAs are of biological origin and encapsulated in a natural human cell membrane.

No genome insertion

Not a lentiviral vector : no reverse transcription, no integrase, for a completely safe solution.

Highly efficient

A broad tropism and a capacity to modify any type of cells, even very sensitive ones.

Short-term & transient expression

Fast expression of the proteins of interest. A duration of expression related to the half-life of the protein.

Proprietary

Intellectual property fully protected, independently from LNP technology.

Our fields of application

Gene therapy

Fast and transient expression of one or several protein(s) of interest in one shot. First in Human trial in 2025 (treatment of secondary lymphedema through the simultaneous expression of two factors).

Genome edition

All-in-One system for a transient expression of the CRISPR-Cas9 system : very low off target risk. Proven efficiency for base editing approaches as well.

Cell reprogramming

Gentle for sensitive cells, but efficient in the delivery of up to four reprogramming factors at once. Proven efficiency in iPSC.

Vaccination

Fast protein expression with no adverse immune responses. 500 times more powerful than LNP for Covid vaccination with an equivalent RNA dose.

Immunotherapy

Low immunogenicity. Multiple (up to 4) and large (up to 10 kb) RNA delivery allowing concomitant delivery of antigens, immuno modulatory molecules and more…

Your application

FlashRNA^® may be the ideal solution for your project as well.

Let’s explore the potential together!

Accelerate Innovation
Transform Gene Therapy with RNAlead

Our Mission

At RNAlead, our mission is to provide our partners with a proprietary RNA delivery technology that is powerful, versatile, and proven. We support our clients, big pharmas, biotechs or academic research teams, throughout their innovation journey — from early-stage research to clinical applications — with a flexible solution designed to meet the evolving demands of modern gene and cell therapies. We are continuously optimizing our platform to enable targeted delivery to specific cell types in vivo, expanding its therapeutic potential and real-world impact.

Our Vision

We believe in a future where medicine is faster, more precise, and more accessible. With the unmatched versatility of our platform, we unlock a broad range of therapeutic applications with a bold ambition: to become the standard of care for RNA delivery. Our goal is to accelerate access to next-generation treatments by offering our clients a true performance driver and a strategic advantage in the market.

The scientific expertise at RNAlead is fueled by a dedicated team of experienced professionals who strongly believe that our extensive experience with the FlashRNA^® technology qualifies us as the ideal partner for (co)developing new and innovative therapies with you. We are dedicated to addressing the challenges posed by new projects with agility, expertise, tailor-made approach and enthusiasm. We firmly believe that our extensive experience with FlashRNA^® technology qualifies us as the ideal partners for developing new and innovative therapies.

Our objective is to ensure broad access to efficient solutions for tomorrow’s medicine through RNA delivery.

Christine Duthoit, PhD
CEO – CSO

RNAlead was born from a strong conviction : biotherapy needs smarter, more accessible delivery solutions to meet tomorrow’s challenges. With FlashRNA^®, we’ve built a proprietary technology designed to reshape the rules of the game.

Our ambition is clear — to be a key player in tomorrow’s medicine, alongside the innovators who dare to lead.

Valentin Alsat
COO – CFO

Our team

We are a dedicated team of 7 passionate professionals cumulating more than 70 years of expertise in the field of nucleic acid transfer and delivery.

We combine deep, cross-functional expertise in FlashRNA^® technology and its R&D to GMP production process — built on a strong foundation of shared experience and a unified vision.

Our biggest supporters

« Our investment strategy is based on strong convictions and in-depth investigations of promising companies in Healthcare and Technology. Our role as a catalyst in the transformation of these companies, is helping them become French leaders, reach European status, and potentially expand globally ».